Much was made of the likely rise of the medtech industry during the pandemic, which was understandable given the circumstances. Covid-19 precipitated a marked increase in the number of related deals, and their representative value. But clinical and cost-related imperatives have not altered since then, even if they’ve become less immediate.

The lockdowns not only resulted in the widespread cessation of elective surgical procedures and screening programmes, but the consequent disruption to normal human interactions also altered our relationships with local GPs. Clearly, the pandemic upended existing norms, but there can be no doubt that we are witnessing a shift away from traditional inpatient settings.